Overview

Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients

Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
Study of ANA001 in Moderate and Severe COVID-19 Patients
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
ANA Therapeutics
NeuroBo Pharmaceuticals Inc.
Treatments:
Niclosamide